TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,769,642 | +113.5% | 441,019 | +212.7% | 2.06% | +132.9% |
| Q1 2023 | $3,170,107 | -60.2% | 141,019 | -62.8% | 0.88% | -64.0% |
| Q4 2022 | $7,963,189 | +73.8% | 379,019 | +103.8% | 2.46% | +67.4% |
| Q3 2022 | $4,582,000 | -98.8% | 186,019 | +1918.7% | 1.47% | -62.9% |
| Q2 2022 | $380,000,000 | +24416.1% | 9,215 | -97.6% | 3.96% | +1032.6% |
| Q1 2022 | $1,550,000 | -86.9% | 380,000 | 0.0% | 0.35% | -86.7% |
| Q4 2021 | $11,803,000 | +28.1% | 380,000 | 0.0% | 2.63% | +18.3% |
| Q3 2021 | $9,215,000 | +3055.8% | 380,000 | +1800.0% | 2.22% | +2787.0% |
| Q2 2021 | $292,000 | -41.5% | 20,000 | 0.0% | 0.08% | -41.7% |
| Q1 2021 | $499,000 | -8.4% | 20,000 | 0.0% | 0.13% | -11.4% |
| Q4 2020 | $545,000 | – | 20,000 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,028,875 | $25,351,000 | 8.34% |
| GREAT POINT PARTNERS LLC | 966,108 | $23,805,000 | 5.73% |
| Deep Track Capital, LP | 4,000,000 | $98,560,000 | 4.51% |
| RA Capital Management | 4,922,941 | $121,301,000 | 2.59% |
| ARMISTICE CAPITAL, LLC | 5,836,000 | $143,799,000 | 2.49% |
| Kynam Capital Management, LP | 416,729 | $10,268,000 | 2.16% |
| MPM BioImpact LLC | 276,460 | $6,812,000 | 1.61% |
| HighVista Strategies LLC | 110,698 | $2,728,000 | 1.56% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 186,019 | $4,582,000 | 1.47% |
| SECTORAL ASSET MANAGEMENT INC | 249,700 | $6,153,000 | 1.21% |